Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…
Abstract Number: 1517 • 2016 ACR/ARHP Annual Meeting
Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Hannah Jethwa¹, Suzanne Lam², Colette Smith³ and Ian Giles⁴, ¹General Medicine, Wexham Park Hospital, London, United Kingdom, ²Croyden University Hospital, London, United Kingdom, ³Statistics, Royal Free Hospital Foundation Trust, London, United Kingdom, ⁴Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is considered to improve in approximately 75% of patients with rheumatoid arthritis (RA) during pregnancy. This figure, however, is derived from…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer E. Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon M. Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁶Hackensack Univ Med Ctr, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Mikhail Kostik¹, Ekaterina Gaidar¹, Margarita Dubko¹, Ludmila Snegireva², Vera Masalova², Irina Chikova¹, Eugenia Isupova³, Tatiana Nikitina⁴, Elena Serogodskaya¹, Olga Kalashnikova¹, Angelo Ravelli⁵ and Vyacheslav Chasnyk³, ¹State Pediatric Medical University, Saint-Petersburg, Russia, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ⁴State Pediatric Medical University, St. Petersburg, Russia, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 930 • 2015 ACR/ARHP Annual Meeting
Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis
Edward J. Oberle^1,2, James Nocton³ and Arthur Meyers⁴, ¹Pediatrics, Ohio State University, Columbus, OH, ²Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Radiology, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Temporomandibular joint (TMJ) arthritis is a common yet widely under recognized feature of Juvenile Idiopathic Arthritis (JIA). It is often clinically silent and difficult…
Abstract Number: 2444 • 2015 ACR/ARHP Annual Meeting
Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis
Mette Noergaard¹, Johanne Lomholt², Mikael Thastum², Morten Herlin³, Marinka Twilt⁴ and Troels Herlin⁴, ¹Department of Physiotherapy, Aarhus University Hospital, Aarhus, Denmark, ²Psychology and Social Sciences, Aarhus University, Aarhus, Denmark, ³Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) has been associated with decreased physical activity (PA). However, accurate, objective measurements of PA related to potential factors limiting PA…
Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting
Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Anuj Shukla¹, Priyanka Gaur² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…
Abstract Number: 2445 • 2015 ACR/ARHP Annual Meeting
Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents
Jennifer N. Stinson¹, Adam M. Huber², Mark Connelly³, Nadia Luca⁴, Lynn R. Spiegel⁵, Argerie Tsimicalis⁶, Stephanie Luca⁷, Roberta Berard⁸, Julie Barsalou⁹, Sarah Campillo¹⁰, Paul Dancey¹¹, Ciarán M. Duffy¹², Brian Feldman¹³, Nicole Johnson⁴, Patrick McGrath¹⁴, Natalie J. Shiff¹⁵, Shirley M Tse¹⁶, Lori B. Tucker¹⁷ and J. Charles Victor¹⁸, ¹Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ²Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Psychology, University of Kansas Medical Center, Kansas City, KS, ⁴Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ⁵Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada, ⁸Children's Hospital of Western Ontario, London, ON, Canada, ⁹CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁰Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, ¹¹Health Science Centre, Memorial University of Newfoundland, St Johns, NF, Canada, ¹²Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹³Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁴IWK Health Centre, Halifax, NS, Canada, ¹⁵Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹⁶Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness that can negatively impact health-related quality of life (HRQL). In younger years, children manage…
Abstract Number: 958 • 2015 ACR/ARHP Annual Meeting
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Jens Klotsche¹, Gerd Ganser², Ivan Foeldvari³, Hans Huppertz⁴, Rolf M. Kuester⁵, Angelika Thon⁶, Kirsten Minden⁷ and Gerd Horneff⁸, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁴Prof Hess Children’s Hospital, Bremen, Germany, ⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ⁶Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, ⁷Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…
Abstract Number: 2446 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course
AnneMarie C. Brescia¹, Megan M. Simonds², Kathleen E. Sullivan³ and Carlos D. Rose⁴, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE, ³Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Children with oligoarticular juvenile idiopathic arthritis (JIA) who have an extended course (recruitment of 5 or more joints after 6 months of disease) have…
Abstract Number: 1293 • 2015 ACR/ARHP Annual Meeting
A Comparison of Prenatal Care in Mothers with and without JIA: Association with Outcomes
Debbie Ehrmann Feldman¹, Anick Bérard², Evelyne Vinet³, Ciarán M. Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Sasha Bernatsky⁸, ¹School of Rehabilitation, Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Université de Montréal, Montreal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Women who had JIA in childhood and adolescence may be at higher risk for adverse neonatal and maternal outcomes. Our objective was to examine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].